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HepatocyteCyclic AMP inhibits the expression of nitric oxide synthase (Harbrecht et al., 1995 [1]) in hepatocytes but the
mechanism for this effect is incompletely understood. Cyclic AMP can activate several intracellular signaling
pathways in hepatocytes including Protein Kinase A (PKA), cAMP regulated guanine nucleotide exchange factors
(cAMP-GEFs), and calcium-mediatedProteinKinases. There is considerableoverlap and cross-talk betweenmany
of these signaling pathways, however, and how these cascades regulate hepatocyte iNOS is not known. We
hypothesized that Akt mediates the effect of cAMP on hepatocyte iNOS expression. Hepatocytes cultured with
cytokines and dbcAMP increased Akt phosphorylation up to 2 h of culture. Akt phosphorylationwas inhibited by
thePI3K inhibitor LY294002(10 μM), farnyltranferase inhibitor FTI-276, or transfectionwith adominantnegative
Akt. The cyclic AMP-induced suppression of cytokine-stimulated iNOS was partially reversed by LY294002 and
FTI-276. LY294002 also increased NFκB nucleus translocation byWestern blot analysis in nuclear extracts. Cyclic
AMP increased phosphorylation of Raf1 at serine 259 which was blocked by LY294002 and associated with
decreasedMAPK P44/42 phosphorylation. However, inhibition ofMAPK P44/42 signalingwith PD98059 failed to
suppress cytokine-induced hepatocyte iNOS expression and did not enhance the inhibitory effect of dbcAMP on
iNOS production. A constitutively active MAPK P44/42 plasmid had no effect on cytokine-stimulated NO
production. These data demonstrate that dbcAMP regulates hepatocyte iNOS expression through an
Akt-mediated signaling mechanism that is independent of MAPK P44/42.Building, Room 317, Louisville,
52 1256.
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Hepatocyte nitric oxide synthase [1] expression is an integral part
of the response to a variety of proinﬂammatory stimuli such as
hemorrhagic shock and sepsis [1–4]. Excessive nitric oxide (NO) from
induced NOS (iNOS) can produce hepatic injury and hepatic
dysfunction while global elimination of all NO synthesis in vivo
inhibits vascular perfusion and other important physiologic and
cellular pathways [3–7]. Therefore, fully understanding the regulation
and function of NO is necessary to understand hepatic physiology and
function in shock and sepsis. A more thorough understanding of the
role of NO synthesis in these states is essential if this pathway is to be
manipulated for therapeutic purposes.
We have shown that glucagon regulates hepatic NOS both in vitro
and in vivo [8–10]. Glucagon receptors lead to calcium mobilization
and stimulation of adenylate cyclase to activate a number of
downstream signaling cascades, protein kinases, and phosphatasesthat ultimately regulate intracellular gene expression [11–14]. In
hepatocytes, the regulation of iNOS by glucagon appears to be due
primarily to the actions of the second messenger cAMP and
subsequent alterations in NF-κB and JNK [9,15]. However, other
signaling pathways can be regulated by glucagon and cAMP that may
also contribute to iNOS regulation. Cyclic AMP regulates mitogen
activated protein (MAP) kinase activity and can either increase or
decrease MAP kinase signaling depending on the different cell type
[16,17]. Cyclic AMP regulates Akt phosphorylation and activation in
hepatocytes [18–20]. In hepatocytes, camp decreased MAPK p44/
42activation induced by epidermal growth factor [17,21,22]. cAMP
also decreased MAPK p44/42activity in primary hepatocytes inde-
pendent of PI3K or Akt [23] but has no effect on MAPK p44/42 in
hepatoma cells [24]. Both MAP kinase and Akt exert strong regulatory
effects on hepatocyte gene expression and hepatocellular function
[25–30] but the role of Akt andMAP kinase, speciﬁcally MAPK p44/42,
in mediating the effects of cAMP on hepatocyte iNOS expression is
unknown. We therefore investigated the role of Akt in mediating the
inhibition of iNOS expression produced by cAMP. Our data demon-
strate that Akt regulates, in part, hepatocyte iNOS expression
following exposure to cytokines and dbcAMP but does so independent
of MAPK p44/42activation.
Fig. 1. IL-1β+IFNγ and dbcAMP induce Akt phosphorylation in hepatocytes.
Hepatocytes were treated with IL-1β (200 U/ml)+IFNγ (100 U/ml) with or without
dbcAMP (0.5 mM) and cells were harvested at the indicated time point forWestern blot
analysis. A: Early time point. B: Late time point. The blots shown are representative of
three independent experiments.
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2.1. Materials
Williams Medium E, penicillin, streptomycin, L-glutamine and
HEPES were all from Invitrogen Corporation (Carlsbad, CA). Insulin
was from Lilly (Indianapolis, IN). Polyclonal antibodies to iNOS, NFκB
and IkBαwerepurchased fromBDBioscience (Billerica,MA).Antibodies
to Raf1 (phosphorylated at serine 259 and total), Akt (total and
phosphorylated at serine 473),MEK1/2 (total and phosphorylated at ser
217/ser 221), MAPK p44/42(total and phosphorylated at Thr 203/Thr
204), and actin were purchased from Cell Signaling Technology
(Danvers, MA). Antibody to PCNA was purchased from Santa Cruz
biotechnology (Santa Cruz, CA). LY294002 (10 mM liquid product in
DMSO) and PD98059 (dissolved and re-suspended with DMSO to
different concentration at 5, 10, 15 and 20 mM) were purchased from
Calbiochem (San Diego, CA). Human recombinant interleukin 1β
(IL-1β) was from Dupont (Boston, MA) and murine recombinant
interferonγ (IFN)was from Invitrogen Life Technologies (Carlsbad, CA).
The plasmid expressing dominant negative Akt was provided by Drs.
Burgering and Triest from Utrecht University, Belgium. The plasmid
expressing constitutively active MAPK P44/42 was provided by
Dr. Wang from the University of Pittsburgh. FTI-276 (re-suspended to
10 mM with water) and all other reagents were from Sigma (St. Louis,
MO).
2.2. Primary hepatocyte isolation and culture
Primary hepatocytes were isolated from male Sprague–Dawley
rats (200–250 g) using the modiﬁed collagenase perfusion technique
as previously described [31]. Puriﬁed hepatocytes (N98% pure with
N95% viability by trypan blue exclusion) were cultured onto collagen-
coated 100 mm dishes in Williams Medium E with L-arginine
(0.5 mM), L-glutamine (2 mM), HEPES (15 mM) penicillin, strepto-
mycin and 10% low endotoxin calf serum (HyClone Laboratories,
Logan, UT) for 4 h, then cells were washed to remove non-attached
cells and media was replaced with insulin-free media with 5% calf
serum. After 16 h of further incubation, the experimental conditions
were established. Conditionswere performed in duplicate or triplicate
and experiments were repeated three times to ensure reproducibility.
2.3. Preparation of nuclear extract
A modiﬁcation of the method by Schreiber et al. [32] was used for
preparation of primary hepatocyte nuclear extracts. Primary hepatocytes
were washed with cold phosphate-buffered saline (PBS). After centrifu-
gation, the cell pellets were frozen at −80 °C for at least 1 h and
resuspended in 500 μl buffer A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2,
10 mM KCl, 0.5% NP40). After 10 min of incubation on ice, cells were
centrifuged for 10 min at 6000 rpm. Nuclei were then washed with
500 μl buffer A without NP40 and centrifuged for 10 min at 6000 rpm.
The supernatant was collected as cytosolic protein and the pellet was
then resuspendedand salt extracted in200μl buffer B (20 mMHEPES [pH
7.9], 25% glycerol [v/v], 1.5 mM MgCl2, 0.5 mM ethylenediaminetetraa-
cetic acid [EDTA], 0.5 M NaCl) on ice for 30 min. All buffers included
0.5 mM DTT (dithiothreitol), 0.2 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml
pepstatin A, and 1 μg/ml chymostatin. After centrifugation at 20,000×g
for 30 min, supernatantswere collected, aliquoted, and stored at−80 °C.
Protein concentration was measured using bicinchoninic acid (BCA)
protein assay reagent (Pierce Chemical Company, Rockford, IL).
2.4. Western blot
Hepatocytes were washed with ice-cold PBS and then scraped from
the plate in 500 μl of lysis buffer (20 mMTris–HCl, pH7.5, 150 mMNaCl,
1 mM Na2-EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophos-phate, 1 mMβ-glycerophosphate, 1 mMNa3VO4, 1 μg/ml leupeptin, and
1 mM PMSF). After 30 min at 4 °C, the lysates were centrifuged
(15,000×g for 15 min) and stored at −80 º C until use. Proteins were
separated on SDS-PAGE and transferred to nitrocellulose membranes.
Nonspeciﬁc binding was blocked with TBS-T (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 0.1% Tween 20) containing 5% non-fat milk for 1 h.
Primary antibodies were diluted and incubated with membranes for
1–2 h at room temperature or overnight at 4 °C with agitation. After
washing three times with TBS-T, secondary antibodies were incubated
at 1:10,000 dilution for 1 h. After 5 additional washes with TBS-T, the
bands were visualized with chemiluminescence according to the
manufacturer's instructions.2.5. Plasmid transfection
Hepatocytes were plated in 6-well plates (4×105cells/well) and
transfected with plasmids as previously described [15]. Brieﬂy,
plasmids were transfected using LipofectAMINE for 6 h, allowed to
recover overnight, and the experimental conditions were established.
The transfection efﬁciency by this method is approximately 30% for
primary hepatocytes.2.6. NO measurement
SupernatentNO2−wasmeasured as an indexofNOproduction by the
Griess reaction as described [10]. Data are presented as the mean±SD
and analysis of variance (ANOVA) was used to determine statistical
signiﬁcance.3. Results
3.1. cAMP increases Akt phosphorylation
Cyclic AMP increased Akt phosphorylation in cultured hepatocytes
[18–20] but not in hepatoma cells [24]. To investigate the role of Akt
signaling in hepatocyte iNOS expression, we measured Akt phosphory-
lation in the presence and absence of dbcAMP in cultured hepatocytes
exposed toproinﬂammatory cytokines (IL-1β+IFNγ). BothdbcAMPand
IL-1β+IFNγ increased Akt phosphorylation but the greatest stimulation
ofAkt occurred inhepatocytes stimulatedwith IL-1β+IFNγanddbcAMP
(Fig. 1). dbcAMP induced a prolonged Akt phosphorylation lasting up to
16 hof culture,while the IL-1β+IFNγ -inducedAktphosphorylationwas
brief.
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Akt is phosphorylated by the activation of upstream kinases such as
PI3K [20,25,33] To test the hypothesis that cAMP-induced activation of
Akt regulates hepatocyte iNOS expression, isolated hepatocytes were
stimulated to induce NOS by IL-1β+IFNγ in the presence and absence
of dbcAMP (0.5 mM). LY294002 (10 μM) was used to inhibit Akt
activation. IL-1β+IFN increased hepatocyte iNOS expression and this
expression was inhibited by dbcAMP (Fig. 2). LY294002 partially
reversed the inhibitory effect of dbcAMP on iNOS expression (Fig. 2A)
and NO2− accumulation (Fig. 2B), while signiﬁcantly inhibiting Akt
phosphorylation (Fig. 2C). LY294002 was also associated with a slight
increase in iNOS expression and NO2− accumulation in IL-1β+IFN-
treated hepatocytes (Fig. 2). To conﬁrm the results of this experiment,
we transfected hepatocytes with a dominant negative Akt plasmid and
then stimulated them with IL-1β+IFN in the presence and absence of
dbcAMP. Overexpression of a dominant negative Akt decreased
dbcAMP-induced Akt phosphorylation (Fig. 2D) and partially reversed
the inhibiting effect of dbcAMP on cytokine-stimulated hepatocyte NO2−
production (Fig. 2E). The concentration of dbcAMP (0.5 mM) used in
theseexperiments suppressedNOproduction asmeasuredby theGriess
reaction (data not shown) as previously demonstrated [8,10].3.3. Ras mediates the effect of cAMP on iNOS
Akt can also be phosphorylated by Ras [34,35]. Akt phosphorylation
induced by IL-1β+IFNγ and dbcAMP was reduced by culturing
hepatocytes with a farnesyltransferase inhibitor (FTI-276) 10 μM to
inhibit Ras activity (Fig. 3A). Inhibiting Ras with FTI (10 μM) partiallyFig. 2. PI3K mediates the effects of cAMP on Akt phosphorylation and iNOS production. A: H
stimulated with IL-1β+IFNγ with or without 0.5 mM dbcAMP. After 24 h, cell lysates wer
representative of three independent experiments. B: Hepatocytes were treated as in A an
incubated with 10 μM P13K inhibitor (LY294002) for 30 min, and then stimulated with IL
Western blot analysis and probed with antibodies against phosphorylated Akt (s473) a
D. Hepatocytes were transfected with a dominant negative Akt expression plasmid (AktKD)
subjected to Western blot with Akt antibody. The blot shown is representative of three inde
dominant negative Akt (Akt KD). The cells were stimulated with IL-1β+IFN with or withou
assay. In B and E, the data represent the mean±S.D. from three independent experiments.reversed the inhibitory effect of dbcAMP on IL-1β+IFNγ -induced
hepatocyte iNOS expression (Fig. 3B).
3.4. cAMP decreases Raf1 and MAPK p44/42activation
Akt activation can alter the activity of downstream signaling
pathways such as NF-κB and MAPK P44/42[19,25,36–40]. MAPK P44/
42activation mediates the up regulation of iNOS expression by
cytokines in macrophages [41], vascular smooth muscle cells [42],
and cardiac myocytes [43]. We therefore tested the hypothesis that
Akt activation regulates hepatocyte iNOS expression through regula-
tion of the Raf/MEK/MAPK P44/42pathway. Since Akt phosphorylates
Raf1 at serine 259 (pRaf1) to inhibit Raf/MEK/MAPK P44/42 signaling
[44], we ﬁrst measured pRaf1 phosphorylation at serine 259 in
hepatocytes. Hepatocytes cultured alone or with IL-lβ+IFN had little
pRaf-1 immunoreactivity (Fig. 4A). Incubation of hepatocytes with
dbcAMP (0.5 mM) increased pRaf1 which was increased further in
hepatocytes cultured with dbcAMP and IL-lβ+IFN (Fig. 4A). cAMP
also decreased IL-1β+IFN-induced phosphorylation of MEK (Fig. 4B)
and MAPK p44/42(Fig. 5A) which is consistent with the work of
others [17,21–23].
3.5. cAMP-induced MAPK P44/42 inhibition does not inhibit hepatocyte
iNOS
Todirectly test the role ofMAPKP44/42 signaling on hepatocyte iNOS
expression,we stimulated hepatocytes to produce iNOSwith IL-1β+IFN
in the presence and absence of the MEK inhibitor PD98059 to decrease
MAPK P44/42activity. PD98059 decreased IL-lβ+IFN-induced MAPK
P44/42 phosphorylation but did not alter IL-lβ+IFN-induced NO2−epatocytes were pre-incubated with 10 μM of the PI3K inhibitor, LY 294002, and then
e subjected to Western blot analysis using a speciﬁc iNOS antibody. The blot shown is
d superantants analyzed for nitrite using the Griess assay. C. Hepatocytes were pre-
-1β+IFNγ with or without 0.5 mM dbcAMP for 30 and 60 min. Cells were lysed for
nd total Akt. The blot shown is representative of three independent experiments.
for 24 h and stimulated with 0.5 mM dbcAMP for 0, 15 or 30 min. The cell lysates were
pendent experiments. E: Hepatocytes were transfected with a plasmid that expresses a
t 0.5 mM dbcAMP. After 24 h, the supernatant was analyzed for nitrite using the Griess
**pb0.05 versus vector transfection group, n=6.
Fig. 3. Ras is involved in cAMP-induced Akt phosphorylation and its inhibitory effect on
iNOS expression. A: Hepatocytes were pre-incubated with 10 μM farnesyltransferase
inhibitor FTI-276 (dissolved inwater accounting tomanufacturers' instruction) for 30 min,
and then stimulated with IL-1β+IFNγ with or without 0.5 mM dbcAMP for 60 min. Cells
were lysed for Western blot analysis and probed with antibodies against phosphorylated
Akt (s473) and total Akt. B: Hepatocytes were pre-incubated with 10 μM of the Ras
inhibitor, FTI-276, and then stimulated with IL-1β+IFNγ with or without 0.5 mM
dbcAMP. After 24 h, cell lysates were subjected to Western blot analysis using a speciﬁc
iNOS antibody. The blots shown are representative of three independent experiments.
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effect of dbcAMP on iNOS expression and production. We conﬁrmed the
effect of PD98059 on iNOS regulation by transfecting hepatocytes with a
plasmid that expresses constitutively active MAPK P44/42 (Fig. 5C).
OverexpressingMAPK P44/42 had no effect on cytokine-stimulated iNOS
activation or on the inhibition of iNOS produced by dbcAMP (Fig. 5C).
These data demonstrate that the cytokine- and dbcAMP-induced
activation of Akt decreases MAPK P44/42in cultured hepatocytes but
that MAPK P44/42does not mediate the inhibition of iNOS expression
produced by cAMP.
3.6. PI3K inhibitor affects NFκB nucleus translocation
We previously showed that cAMP decreased IL-lβ+IFNγ-induced
NFκB DNA binding and p65 translocation [9,45]. To test if cAMP/Akt
signaling mediates the effect of cAMP on p65 translocation,
hepatocytes were pre-incubated with the PI3K inhibitor to attenuate
Akt activation and then treated with IL-lβ+IFNγ with or withoutFig. 4. dbcAMP increases hepatocyte Raf1 (s259) phosphorylation and decreases MEK1/2 ph
or without dbcAMP (0.5 mM) for the indicated time and cell lysates were harvested for W
(ser259) (A), p-MEK1/2 and total MEK1/2 (B). The blots shown are representative of threedbcAMP. The nuclear extracts and cytosolic proteins were prepared
after 60 min and subjected to Western blot analysis (Fig. 6A). Similar
to our previous work [9,45], IL-lβ+IFNγ increased p65 in nuclear
extracts and this was reduced by dbcAMP (Fig. 6A and B). Inhibition of
PI3K and Akt signaling with LY294002 increased p65 in the nucleus in
IL-lβ+IFNγ-stimulated hepatocytes and reversed the dbcAMP-
induced suppression of nuclear p65 (Fig. 6A and B).
4. Discussion and conclusion
Hepatocyte iNOS expression is regulated primarily by control of
gene transcription [46]. While several transcription factors that
regulate iNOS expression have been identiﬁed [46–48], the intracel-
lular signaling pathways leading to iNOS expression and their speciﬁc
mechanisms are incompletely deﬁned. We have shown that increas-
ing cAMP suppresses cytokine-induced iNOS expression and NO
synthesis in hepatocytes both in vitro and in vivo [8–10].
In hepatocytes, cAMP regulates gene expression and cell function
in via several downstream signaling mechanisms. cAMP induced
hepatic HO-1 gene transcription in a PKA-dependent manner [49,50]
and induced glucose output through Ca2+ [51]. PKA is the most
thoroughly studied pathway in hepatocytes mediating cAMP-induced
changes in gene expression [11–14]. The effect of cAMP on iNOS in
hepatocytes is primarily PKA-independent and involves inhibition of
NF-κB DNA binding and an increase in JNK activation [9,15], but cAMP
also regulates Akt and MAP kinase signaling [16,17,20]. We therefore
investigated the role of Akt and MAPK P44/42 in regulating the
inhibitory effects of cAMP on hepatocyte iNOS expression. Our data
demonstrate that dbcAMP and IL-1β+IFN induce a sustained increase
in Akt phosphorylation and activation. Both cytokine- and cAMP-
induced Akt phosphorylation appear to involve PI3K and Ras since
inhibiting both proximal kinases decreases Akt phosphorylation.
Inhibition of PI3K and Ras also reversed the camp-induced suppres-
sion of iNOS expression. MAP kinases regulate iNOS expression in
other cell types [41–43] and are themselves regulated by Akt [37–39].
Despite demonstrating that cAMP-induced Akt activation regulates
Raf/MEK/MAPK P44/42 signaling in hepatocytes, however, we could
ﬁnd no role for MAPK P44/42 activation in the regulation of iNOS
expression by cytokines or dbcAMP. MAPK P44/42 can regulate the
expression of a number of genes [27–29]. It is possible that other
hepatocyte genes are regulated by Raf/MEK/MAPK P44/42 signaling
and are altered by cAMP through this pathway but identifying those
genes will require further investigation.
The speciﬁc mechanism for the regulation of iNOS expression by
Akt has not yet been deﬁned. Akt can regulate the activation of other
signaling pathways besides Raf/MEK/MAPK P44/42including NF-κB
and JNK [25,29,52,53]. Akt phosphorylation increases NF-κBosphorylation. Hepatocytes were treated with IL-1β (200 U/ml)+IFN (100 U/ml) with
estern blot analysis. The membranes were probed with antibodies speciﬁc for p-Raf1
independent experiments.
Fig. 5. Decreased hepatocyte MAPK P44/42phosphorylation by cAMP does not regulate hepatocyte iNOS expression. A: Hepatocytes were treated with IL-1β (200 U/ml)+IFN
(100 U/ml) with or without dbcAMP (0.5 mM) for the indicated time and cell lysates were harvested forWestern blot analysis. The membranes were probed with antibodies speciﬁc
for and pMAPK P44/42 and tMAPK P44/42. B. Hepatocytes were incubated with PD98059 at indicated concentration for 30 min and then stimulated with IL-1β (200 U/ml)+IFN
(100 U/ml) for 24 h for the Griess assay (left panel) and Western blot analysis to iNOS (right panel, upper) or 60 min for Western blot analysis with antibodies against
phosphorylatedMAPK P44/42 or total MAPK P44/42. C: Hepatocytes were transfected with a control plasmid (light gray) or plasmid that expresses a constitutively active MAPK P44/
42 (dark gray) and then stimulated to produce NO in the presence or absence of dbcAMP (0.5 mM). Supernatants were collected after 24 h and analyzed for nitrite (left panel) or
harvest cells after 60 min for Western blot analysis (right panel). Data indicate mean±S.D. from three independent experiments, n=6. The blots shown are representative of three
independent experiments.
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expression [46]. In our experiments, LY294002 increased NF-kB
nucleus translocation and may partially mediate cAMP's effects on
iNOS. This is consistent with our previous ﬁnding that dbcAMP
produced a decrease in NF-κB DNA binding in cytokine-stimulated
hepatocytes [9,45].
As discussed above, Akt also regulates JNK in some cells and can
both downregulate [52–54] and upregulate [55] JNK activation. How
Akt and JNK interact in hepatocytes and mediate inﬂammation-
induced gene expression is unknown. Cytokines increase JNK
phosphorylation and subsequent c-Jun-mediated gene regulation
[15] in cultured hepatocytes. Cyclic AMP also increases JNK signaling
and this pathway mediates, in part, the inhibition of iNOS expression
by dbcAMP [15]. Whether cAMP regulates JNK activation through Aktis not yet known. There is evidence that cAMP activate PI3K/Akt
signaling through cAMP-GEF pathway [18]. Akt can also regulate the
activity, either directly or indirectly, of several transcription factors
such as CREB, C/EBP, and Foxo1 that could potentially contribute to
the regulation of iNOS expression [26,56,57]. Determining whether
Akt regulates hepatocyte gene expression in general, and hepatocyte
iNOS expression more speciﬁcally, through these transcription factors
is currently being investigated.
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Fig. 6. PI3K inhibitor regulates NFκB nuclear translocation. Hepatocytes were pre-incubated with 10 μM LY294002 for 30 min and then stimulated with IL-1β (200 U/ml)+IFNγ
(100 U/ml) with or without 0.5 mM dbcAMP. The cells were collected after 60 min for nuclear extracts and cytosolic proteins. Proteins were subject to Western blot analysis by
polyclonal antibodies against NFκB (p65) (A) and IκBα (B) antibodies. B shows digitalized results from 3 blots of A. The ratios of sum density of p65 bands to PCNA bands were
calculated and then normalized by Media with DMSO group. The data represent the mean±S.D. from three independent scans, *pb0.05 vs. DMSO. The blots shown are
representative of three independent experiments.
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